|
[1]Keeffe EB, Zeuzem S, Koff RS, et al.Report of an InternationalWorkshop:Roadmap for Management of Patients Receiving OralTherapy for Chronic Hepatitis B[J].Clin Gastroenterol Hepatol, 2007, 5 (8) ∶890-897.
|
|
[2]Lai CL, Gane E, LiawYF, et al.Telbivudine versus Lamivudine inPatients with Chronic Hepatitis B[J].N Engl J Med, 2007, 357 (12) ∶2576-88.
|
|
[3]Di Bisceglie AM, Lai CL, Gane E, et al.Telbivudine GLOBE trial:Maximal early HBVsuppression is predictive of optimal two-year ef-ficacy in nucleoside-treated hepatitis B patients[J].Hepatology.2006, 44 (4 Suppl.1) ∶230A (abstract 112) .
|
|
[4]贾继东, 侯金林, 尹有宽, 等.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志, 15 (5) ∶342-345.
|
|
[5]Hou J, Yin YK, Xu D, et al.Telbivudine versus lamivudine in Chi-nese patients with chronic hepatitis B:Results at 1 year of arandomized, double-blind trial[J].Hepatology, 2007, 47 (2) ∶447-454.
|
|
[6]Zeuzem S, Buti M, Gane EJ, et al.Baseline Parameters PredictBoth Early Virologic Response And Longer TermOutcomes For Telbi-vudine-Treated Patients With Chronic Hepatitis B (The GLOBEStudy) [J].Hepatology, 2007, 46 (Suppl 1) ∶681A.
|
|
[7]Reddy KR, Rustgi V, Zeuzem S, et al.Week 24 is the OptimalTime Point for Predicting Outcomes at2 Years with Telbivudine[J].Global Antiviral J, 2007, 121 (Suppl.2) ∶13 (Abstract 12) .
|
|
[8]Standring DN, Patty A, Chapron C, et al.Resistance Determinationin Patients Experiencing Virologic Breakthrough Following Telbivudi-ne or Lamivudine Therapy in the International GLOBE Trial[J].DDW.2007, Poster Abstract S1781.
|
|
[9]Gane E, Lai C-L, Min A, et al.Adefovir salvage therapy for viro-logic breakthrough in Telbivudine-treated patients from the GLOBEstudy[J].J Hepatology, 2007, 46 (Suppl 1) ∶S187.
|
PDF下载 ( 421 KB)
本文二维码
下载:
